GC Green Cross Receives Thai IND Approval for Phase 3 Trial of Two-Dose Varicellazoo

Aiming to Secure Final Report by the Second Half of 2027

GC Green Cross announced on October 17 that its clinical phase 3 trial protocol (IND) for the two-dose regimen of its varicella vaccine, Varicellazoo, has received approval from the Thai Food and Drug Administration.

GC Green Cross headquarters exterior in Yongin, Gyeonggi Province. GC Green Cross

This approval came about a month and a half after submitting the IND in August, and it is known that the regulatory agency granted approval swiftly without requesting any additional information.

GC Green Cross also plans to submit a clinical phase 3 IND for the two-dose regimen of Varicellazoo to the Ministry of Health in Vietnam within this year. The clinical trials in Southeast Asia are scheduled to be completed by the second half of 2027.

Lee Jaewoo, Head of Development at GC Green Cross, stated, "This clinical trial aims to establish evidence for a two-dose varicella vaccine regimen that meets global standards," adding, "Varicellazoo, together with GC Flu, will become one of the flagship vaccines of GC Green Cross."

This content was produced with the assistance of AI translation services.